A Phase 3 interventional study of Tenofovir DF and Zidovudine in HIV Infections, sponsored by Gilead Sciences. Completed at 9 sites in 3 countries. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2018-03-14.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.
Among the 98 studies testing tenofovir in HIV Infections, this one is the 48th largest by enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2006, is one of 16 in phase 3, and was the 50th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →1 of the 98 studies testing tenofovir in HIV Infections is open now. Recruiting first, the newest first:
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 2 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 26 · Phase 3 20 · Phase 4 27
First in 1999; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 99 across the 94 interventional studies. Of the 82 that completed or were terminated, 25 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 98 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
84 studies in HIV Infections by Gilead Sciences: 2 open now, 8 under way, 4 of them phase 3. Of 71 finished, 28 (39%) have results posted.
Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 44th largest by enrollment of the 72 interventional ones that give a count, is one of 5 that started in 2006, is one of 26 in phase 3, and was the 43rd registered.
Gilead Sciences’s HIV Infections studies by the year they started, since 1999.
1 of the studies testing tenofovir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06338826ANRS, Emerging Infectious DiseasesStudy Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 98 studies testing tenofovir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 84 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the efficacy of switching to tenofovir disoproxil fumarate (TDF) compared to continuing stavudine or zidovudine in maintaining virologic suppression in HIV-1 infected children.
Major Inclusion Criteria:
Key Inclusion Criteria for the First 96-Week Extension
Key Inclusion Criteria for the Second and Third 96-Week Extension and Fourth Open-Ended Extension
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tenofovir DF
Drug: Zidovudine · Drug: Stavudine
Tenofovir DF (oral powder or tablet): 300-mg tablets for participants \> 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to \> 37 kg may be switched from the oral powder to the tenofovir DF tablet.
Also known as: Viread®
Zidovudine as prescribed by the investigator prior to study entry (pediatric participants \< 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m\^2 every 8 hours; pediatric participants \> 12 years of age: 300 mg twice daily).
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 48 weeks of exposure to randomized study drug.
Time frame: 48 weeks
Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)
This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: 48 weeks
Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 50 Copies/mL, Snapshot)
This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: 48 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 96 weeks of exposure to TDF.
Time frame: 96 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 144 weeks of exposure to TDF.
Time frame: 144 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 192 Weeks
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 192 weeks of exposure to TDF.
Time frame: 192 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 240 Weeks
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 240 weeks of exposure to TDF.
Time frame: 240 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 288 Weeks
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 288 weeks of exposure to TDF.
Time frame: 288 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 336 Weeks
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 336 weeks of exposure to TDF.
Time frame: 336 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 384 Weeks
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 384 weeks of exposure to TDF.
Time frame: 384 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 432 Weeks
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 432 weeks of exposure to TDF.
Time frame: 432 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 480 Weeks
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 480 weeks of exposure to TDF.
Time frame: 480 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 528 Weeks
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 528 weeks of exposure to TDF.
Time frame: 528 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 48 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 48 weeks of exposure to randomized study drug.
Time frame: 48 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 96 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 96 weeks of exposure to TDF.
Time frame: 96 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 144 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 144 weeks of exposure to TDF.
Time frame: 144 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 192 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 192 weeks of exposure to TDF.
Time frame: 192 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 240 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 240 weeks of exposure to TDF.
Time frame: 240 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 288 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 288 weeks of exposure to TDF.
Time frame: 288 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 336 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 336 weeks of exposure to TDF.
Time frame: 336 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 384 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 384 weeks of exposure to TDF.
Time frame: 384 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 432 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 432 weeks of exposure to TDF.
Time frame: 432 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 480 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 480 weeks of exposure to TDF.
Time frame: 480 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 528 Weeks
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 528 weeks of exposure to TDF.
Time frame: 528 weeks
Change From Baseline in CD4 Percentage at 48 Weeks
This is the change from baseline in CD4 percentage after 48 weeks of exposure to randomized study drug.
Time frame: Baseline and 48 weeks
Change From Baseline in CD4 Percentage at 96 Weeks
This is the change from baseline in CD4 percentage after 96 weeks of exposure to TDF.
Time frame: Baseline and 96 weeks
Change From Baseline in CD4 Percentage at 144 Weeks
This is the change from baseline in CD4 percentage after 144 weeks of exposure to TDF.
Time frame: Baseline and 144 weeks
Change From Baseline in CD4 Percentage at 192 Weeks
This is the change from baseline in CD4 percentage after 192 weeks of exposure to TDF.
Time frame: Baseline and 192 weeks
Change From Baseline in CD4 Percentage at 240 Weeks
This is the change from baseline in CD4 percentage after 240 weeks of exposure to TDF.
Time frame: Baseline and 240 weeks
Change From Baseline in CD4 Percentage at 288 Weeks
This is the change from baseline in CD4 percentage after 288 weeks of exposure to TDF.
Time frame: Baseline and 288 weeks
Change From Baseline in CD4 Percentage at 336 Weeks
This is the change from baseline in CD4 percentage after 336 weeks of exposure to TDF.
Time frame: Baseline and 336 weeks
Change From Baseline in CD4 Percentage at 384 Weeks
This is the change from baseline in CD4 percentage after 384 weeks of exposure to TDF.
Time frame: Baseline and 384 weeks
Change From Baseline in CD4 Percentage at 432 Weeks
This is the change from baseline in CD4 percentage after 432 weeks of exposure to TDF.
Time frame: Baseline and 432 weeks
Change From Baseline in CD4 Percentage at 480 Weeks
This is the change from baseline in CD4 percentage after 480 weeks of exposure to TDF.
Time frame: Baseline and 480 weeks
Change From Baseline in CD4 Percentage at 528 Weeks
This is the change from baseline in CD4 percentage after 528 weeks of exposure to TDF.
Time frame: Baseline and 528 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks
This is the change from baseline in CD4 cell count after 48 weeks of exposure to randomized study drug.
Time frame: Baseline and 48 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks
This is the change from baseline in CD4 cell count after 96 weeks of exposure to TDF.
Time frame: Baseline and 96 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks
This is the change from baseline in CD4 cell count after 144 weeks of exposure to TDF.
Time frame: Baseline and 144 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks
This is the change from baseline in CD4 cell count after 192 weeks of exposure to TDF.
Time frame: Baseline and 192 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks
This is the change from baseline in CD4 cell count after 240 weeks of exposure to TDF.
Time frame: Baseline and 240 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks
This is the change from baseline in CD4 cell count after 288 weeks of exposure to TDF.
Time frame: Baseline and 288 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks
This is the change from baseline in CD4 cell count after 336 weeks of exposure to TDF.
Time frame: Baseline and 336 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 384 Weeks
This is the change from baseline in CD4 cell count after 384 weeks of exposure to TDF.
Time frame: Baseline and 384 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 432 Weeks
This is the change from baseline in CD4 cell count after 432 weeks of exposure to TDF.
Time frame: Baseline and 432 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 480 Weeks
This is the change from baseline in CD4 cell count after 480 weeks of exposure to TDF.
Time frame: Baseline and 480 weeks
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 528 Weeks
This is the change from baseline in CD4 cell count after 528 weeks of exposure to TDF.
Time frame: Baseline and 528 weeks
Participants were enrolled at study sites in the United States, Panama, and the United Kingdom. The first participant was screened on 28 December 2006. The last study visit occurred on 16 August 2017.
| Milestone | Tenofovir DF | Stavudine or Zidovudine |
|---|---|---|
| Started | 48 | 49 |
| Completed | 44 | 48 |
| Not completed | 4 | 1 |
| Withdrew: Withdrew consent | 2 | 1 |
| Withdrew: Safety, tolerability, or efficacy reason | 2 | 0 |
| Milestone | Tenofovir DF | Stavudine or Zidovudine |
|---|---|---|
| Started | 38 | 41 |
| Completed | 35 | 40 |
| Not completed | 3 | 1 |
| Withdrew: Investigator's discretion | 2 | 0 |
| Withdrew: Safety, tolerability, or efficacy reason | 1 | 0 |
| Withdrew: Withdrew consent | 0 | 1 |
| Milestone | Tenofovir DF | Stavudine or Zidovudine |
|---|---|---|
| Started | 34 | 40 |
| Completed | 27 | 37 |
| Not completed | 7 | 3 |
| Withdrew: Safety, tolerability, or efficacy reason | 4 | 3 |
| Withdrew: Investigator's discretion | 3 | 0 |
| Milestone | Tenofovir DF | Stavudine or Zidovudine |
|---|---|---|
| Started | 27 | 37 |
| Completed | 21 | 27 |
| Not completed | 6 | 10 |
| Withdrew: Safety, tolerability, or efficacy reason | 5 | 4 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: = 18 yr old & tdf approved in adults | 1 | 1 |
| Withdrew: Investigator's discretion | 0 | 1 |
| Withdrew: Withdrew consent | 0 | 1 |
| Milestone | Tenofovir DF | Stavudine or Zidovudine |
|---|---|---|
| Started | 19 | 25 |
| Completed | 9 | 8 |
| Not completed | 10 | 17 |
| Withdrew: Rolled over to study gs-us-311-1269 | 4 | 10 |
| Withdrew: Safety, tolerability, or efficacy reason | 3 | 5 |
| Withdrew: Withdrew consent | 2 | 1 |
| Withdrew: Investigator's discretion | 1 | 1 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 48 weeks of exposure to randomized study drug.
| percentage of participants | Tenofovir DF | Stavudine or Zidovudine | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 | 83.3 (69.8 to 92.5) | 91.8 (80.4 to 97.7) | 85.4 (76.3 to 92.0) |
This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Tenofovir DF | Stavudine or Zidovudine |
|---|---|---|
| Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot) | 88.6 | 89.6 |
This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Tenofovir DF | Stavudine or Zidovudine |
|---|---|---|
| Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 50 Copies/mL, Snapshot) | 75.0 | 81.3 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 96 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96 | 81.6 | 85.4 | 83.5 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 144 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144 | 73.7 | 87.5 | 80.8 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 192 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 192 Weeks | 70.6 | 82.5 | 77.0 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 240 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 240 Weeks | 70.6 | 75.7 | 73.2 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 288 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 288 Weeks | 81.5 | 67.6 | 73.4 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 336 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 336 Weeks | 90.9 | 100.0 | 95.3 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 384 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 384 Weeks | 100.0 | 100.0 | 100.0 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 432 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 432 Weeks | 100.0 | 85.7 | 95.0 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 480 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 480 Weeks | 88.9 | 100.0 | 90.9 |
This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 528 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 528 Weeks | 100.0 | — | 100.0 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 48 weeks of exposure to randomized study drug.
| percentage of participants | Tenofovir DF | Stavudine or Zidovudine | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 48 Weeks | 70.8 | 85.7 | 68.5 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 96 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 96 Weeks | 76.3 | 68.3 | 72.2 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 144 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 144 Weeks | 63.2 | 75.0 | 69.2 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 192 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 192 Weeks | 67.6 | 75.0 | 71.6 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 240 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 240 Weeks | 70.6 | 73.0 | 71.8 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 288 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 288 Weeks | 81.5 | 62.2 | 70.3 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 336 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 336 Weeks | 86.4 | 90.5 | 88.4 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 384 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 384 Weeks | 88.2 | 100.0 | 92.3 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 432 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 432 Weeks | 100.0 | 71.4 | 90.0 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 480 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 480 Weeks | 77.8 | 50.0 | 72.7 |
This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 528 weeks of exposure to TDF.
| percentage of participants | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 528 Weeks | 100.0 | — | 100.0 |
This is the change from baseline in CD4 percentage after 48 weeks of exposure to randomized study drug.
| percentage | Tenofovir DF | Stavudine or Zidovudine | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 48 Weeks | 0.3 ± 4.49 | 1.1 ± 4.73 | 0.6 ± 3.85 |
This is the change from baseline in CD4 percentage after 96 weeks of exposure to TDF.
| percentage | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 96 Weeks | 1.3 ± 4.08 | -0.1 ± 3.60 | 0.6 ± 3.88 |
This is the change from baseline in CD4 percentage after 144 weeks of exposure to TDF.
| percentage | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 144 Weeks | 0.8 ± 5.61 | -0.1 ± 3.83 | 0.3 ± 4.73 |
This is the change from baseline in CD4 percentage after 192 weeks of exposure to TDF.
| percentage | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 192 Weeks | 1.1 ± 5.57 | 0.6 ± 3.69 | 0.8 ± 4.58 |
This is the change from baseline in CD4 percentage after 240 weeks of exposure to TDF.
| percentage | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 240 Weeks | 1.3 ± 5.98 | -0.9 ± 4.13 | 0.1 ± 5.16 |
This is the change from baseline in CD4 percentage after 288 weeks of exposure to TDF.
| percentage | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 288 Weeks | 2.0 ± 6.30 | 0.5 ± 4.77 | 1.3 ± 5.58 |
This is the change from baseline in CD4 percentage after 336 weeks of exposure to TDF.
| percentage | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 336 Weeks | 2.0 ± 7.19 | 0.8 ± 4.01 | 1.4 ± 5.82 |
This is the change from baseline in CD4 percentage after 384 weeks of exposure to TDF.
| percentage | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 384 Weeks | 0.5 ± 7.80 | 1.6 ± 1.90 | 0.9 ± 6.37 |
This is the change from baseline in CD4 percentage after 432 weeks of exposure to TDF.
| percentage | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 432 Weeks | 0.3 ± 6.41 | 2.9 ± 3.53 | 1.1 ± 5.66 |
This is the change from baseline in CD4 percentage after 480 weeks of exposure to TDF.
| percentage | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 480 Weeks | 2.3 ± 7.15 | 5.0 ± 10.00 | 2.9 ± 7.51 |
This is the change from baseline in CD4 percentage after 528 weeks of exposure to TDF.
| percentage | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage at 528 Weeks | 4.5 ± 3.89 | — | 4.5 ± 3.89 |
This is the change from baseline in CD4 cell count after 48 weeks of exposure to randomized study drug.
| cells/mm^3 | Tenofovir DF | Stavudine or Zidovudine | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks | -97 ± 416.4 | -11 ± 280.2 | 2 ± 385.9 |
This is the change from baseline in CD4 cell count after 96 weeks of exposure to TDF.
| cells/mm^3 | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks | -77 ± 408.3 | -56 ± 305.6 | -67 ± 358.3 |
This is the change from baseline in CD4 cell count after 144 weeks of exposure to TDF.
| cells/mm^3 | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks | -139 ± 438.2 | -146 ± 245.3 | -142 ± 345.9 |
This is the change from baseline in CD4 cell count after 192 weeks of exposure to TDF.
| cells/mm^3 | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks | -304 ± 529.0 | -177 ± 288.5 | -233 ± 413.2 |
This is the change from baseline in CD4 cell count after 240 weeks of exposure to TDF.
| cells/mm^3 | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks | -369 ± 529.9 | -296 ± 252.6 | -329 ± 401.7 |
This is the change from baseline in CD4 cell count after 288 weeks of exposure to TDF.
| cells/mm^3 | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks | -346 ± 507.5 | -256 ± 292.5 | -302 ± 414.6 |
This is the change from baseline in CD4 cell count after 336 weeks of exposure to TDF.
| cells/mm^3 | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks | -415 ± 569.4 | -283 ± 252.2 | -350 ± 443.8 |
This is the change from baseline in CD4 cell count after 384 weeks of exposure to TDF.
| cells/mm^3 | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 384 Weeks | -620 ± 635.6 | -305 ± 238.2 | -512 ± 548.8 |
This is the change from baseline in CD4 cell count after 432 weeks of exposure to TDF.
| cells/mm^3 | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 432 Weeks | -795 ± 559.2 | -302 ± 355.2 | -631 ± 545.7 |
This is the change from baseline in CD4 cell count after 480 weeks of exposure to TDF.
| cells/mm^3 | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 480 Weeks | -923 ± 755.4 | -448 ± 469.9 | -813 ± 712.9 |
This is the change from baseline in CD4 cell count after 528 weeks of exposure to TDF.
| cells/mm^3 | Tenofovir DF | (Stavudine or Zidovudine)/TDF | All TDF |
|---|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at 528 Weeks | -710 ± 447.0 | — | -710 ± 447.0 |
Collected over Adverse events (AEs) were reported in the open-label randomized period (Weeks 0-48), and during the extension period when all participants received tenofovir DF.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenofovir DF | 0/48 (0%) | 2/48 (4.2%) | 37/48 (77.1%) |
| Stavudine or Zidovudine | 0/49 (0%) | 2/49 (4.1%) | 35/49 (71.4%) |
| All TDF | 0/89 (0%) | 15/89 (16.9%) | 82/89 (92.1%) |
| Event | Tenofovir DF | Stavudine or Zidovudine | All TDF |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/48 | 0/49 | 2/89 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/48 | 0/49 | 2/89 |
| PharyngotonsillitisInfections and infestations | 1/48 | 0/49 | 1/89 |
| LymphadenitisBlood and lymphatic system disorders | 0/48 | 1/49 | 0/89 |
| Asthmatic crisisRespiratory, thoracic and mediastinal disorders | 0/48 | 1/49 | 0/89 |
| Abdominal adhesionsGastrointestinal disorders | 0/48 | 0/49 | 1/89 |
| DiarrhoeaGastrointestinal disorders | 0/48 | 0/49 | 1/89 |
| AmoebiasisInfections and infestations | 0/48 | 0/49 | 1/89 |
| AppendicitisInfections and infestations | 0/48 | 0/49 | 1/89 |
| CellulitisInfections and infestations | 0/48 | 0/49 | 1/89 |
| Event | Tenofovir DF | Stavudine or Zidovudine | All TDF |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 17/48 | 17/49 | 57/89 |
| Dental cariesGastrointestinal disorders | 1/48 | 1/49 | 22/89 |
| DiarrhoeaGastrointestinal disorders | 4/48 | 1/49 | 20/89 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/48 | 7/49 | 20/89 |
| GastroenteritisInfections and infestations | 3/48 | 4/49 | 18/89 |
| Otitis mediaInfections and infestations | 7/48 | 4/49 | 16/89 |
| PharyngitisInfections and infestations | 1/48 | 0/49 | 16/89 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/48 | 1/49 | 15/89 |
| PyrexiaGeneral disorders | 1/48 | 3/49 | 14/89 |
| PharyngotonsillitisInfections and infestations | 1/48 | 1/49 | 14/89 |
Randomized and Treated Set: participants who were randomized and received at least 1 dose of study drug
| Age, Continuous(years) | Tenofovir DF | Stavudine or Zidovudine | Total |
|---|---|---|---|
| Mean | 7 ± 3.3 | 7 ± 2.6 | 7 ± 3.0 |
| Sex: Female, Male(Participants) | Tenofovir DF | Stavudine or Zidovudine | Total |
|---|---|---|---|
| Female | 27 | 20 | 47 |
| Male | 21 | 29 | 50 |
| Race/Ethnicity, Customized(Participants) | Tenofovir DF | Stavudine or Zidovudine | Total |
|---|---|---|---|
| Hispanic or Latino | 35 | 42 | 77 |
| Not Hispanic or Latino | 13 | 7 | 20 |
| Race/Ethnicity, Customized(Participants) | Tenofovir DF | Stavudine or Zidovudine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 6 | 19 |
| White | 3 | 6 | 9 |
| Mestizo | 28 | 37 | 65 |
| Native Indian (Kuna) | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Tenofovir DF | Stavudine or Zidovudine | Total |
|---|---|---|---|
| United States | 13 | 9 | 22 |
| Panama | 33 | 39 | 72 |
| United Kingdom | 2 | 1 | 3 |
| Height(cm) | Tenofovir DF | Stavudine or Zidovudine | Total |
|---|---|---|---|
| Mean | 118 ± 19.8 | 119 ± 16.7 | 119 ± 18.2 |
| Body Mass Index(kg/m^2) | Tenofovir DF | Stavudine or Zidovudine | Total |
|---|---|---|---|
| Mean | 17.59 ± 3.680 | 16.59 ± 1.762 | 17.08 ± 2.905 |
| Weight(kilograms) | Tenofovir DF | Stavudine or Zidovudine | Total |
|---|---|---|---|
| Mean | 25.9 ± 12.03 | 24.1 ± 7.77 | 25.0 ± 10.09 |
3 further baseline measures are reported on the registry.
Ran from Dec 2006 to primary completion in Apr 2009, 27 months.
Results were first posted in Mar 2012, 2 years 11 months after primary completion. A results delay was requested in Jun 2011.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 27 months is above that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir